Global Erectile Dysfunction (ED) Drugs Market 2026-2030

Description

The global erectile dysfunction (ed) drugs market is forecasted to grow by USD 1756.5 mn during 2025-2030, accelerating at a CAGR of 7.1% during the forecast period. The report on the global erectile dysfunction (ed) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising demand for erectile dysfunction drugs, rising awareness of erectile dysfunction drugs, high prevalence of conditions resulting in erectile dysfunction.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Market Scope
Base Year	2026
End Year	2030
Series Year	2026-2030
Growth Momentum	Accelerate
YOY 2026	6.5%
CAGR	7.1%
Incremental Value	$1756.5 mn

Technavio's global erectile dysfunction (ed) drugs market is segmented as below:

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Product

Oral drugs
Topical drugs
Others

By Type

Sildenafil
Tadalafil
Vardenafil
Avanafil
Others

Geography

North America
- US
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- The Netherlands
- Russia
Asia
Rest of World (ROW)
Rest of World (ROW)

This study identifies the presence of novel drug formulations in late stages of development as one of the prime reasons driving the global erectile dysfunction (ed) drugs market growth during the next few years. Also, expanding research for development of novel therapies and increasing otc abuse of drugs will lead to sizable demand in the market.

The report on the global erectile dysfunction (ed) drugs market covers the following areas:

Global erectile dysfunction (ed) drugs market sizing
Global erectile dysfunction (ed) drugs market forecast
Global erectile dysfunction (ed) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global erectile dysfunction (ed) drugs market vendors that include A. Menarini Industrie Farma, Aseric Pharma, Aurobindo Pharma Ltd., Bayer AG, Cipla Inc., Dong A Socio Holdings Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Lupin Ltd., Nippon Shinyaku Co. Ltd., Pfizer Inc., Sandoz Group AG, Sanofi SA, SK Chemicals Co. Ltd., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd., Viatris Inc., VIVUS LLC. Also, the global erectile dysfunction (ed) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72378

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
2.3 Factors of disruption
2.4 Impact of drivers and challenges

3 Market Landscape

3.1 Market ecosystem
3.2 Market characteristics
3.3 Value chain analysis

4 Market Sizing

4.1 Market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2025
4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

5.1 Global Erectile Dysfunction (ED) Drugs Market 2020 - 2024
- Historic Market Size - Data Table on Global Erectile Dysfunction (ED) Drugs Market 2020 - 2024 ($ million)
5.2 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
5.3 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
5.4 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

6.1 The Impact of AI on the Global Erectile Dysfunction (ED) Drugs Market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
7.7 Market condition

8 Market Segmentation by Distribution Channel

8.1 Market segments
8.2 Comparison by Distribution Channel
8.3 Hospital pharmacy - Market size and forecast 2025-2030
8.4 Retail pharmacy - Market size and forecast 2025-2030
8.5 Online pharmacy - Market size and forecast 2025-2030
8.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Product

9.1 Market segments
9.2 Comparison by Product
9.3 Oral drugs - Market size and forecast 2025-2030
9.4 Topical drugs - Market size and forecast 2025-2030
9.5 Others - Market size and forecast 2025-2030
9.6 Market opportunity by Product
- Market opportunity by Product ($ million)

10 Market Segmentation by Type

10.1 Market segments
10.2 Comparison by Type
10.3 Sildenafil - Market size and forecast 2025-2030
10.4 Tadalafil - Market size and forecast 2025-2030
10.5 Vardenafil - Market size and forecast 2025-2030
10.6 Avanafil - Market size and forecast 2025-2030
10.7 Others - Market size and forecast 2025-2030
10.8 Market opportunity by Type
- Market opportunity by Type ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation
12.2 Geographic comparison
12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 UK - Market size and forecast 2025-2030
- 12.4.2 Germany - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.4.7 Russia - Market size and forecast 2025-2030
12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.5.7 Singapore - Market size and forecast 2025-2030
12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Australia - Market size and forecast 2025-2030
- 12.6.2 Brazil - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 South Africa - Market size and forecast 2025-2030
- 12.6.5 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.6 Turkey - Market size and forecast 2025-2030
12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

13.1 Market drivers
- Rising demand for erectile dysfunction drugs
- Rising awareness of erectile dysfunction drugs
- High prevalence of conditions resulting in erectile dysfunction
13.2 Market challenges
- Availability of generics drugs
- Side-effects of available drugs
- Poor reimbursement scenario
13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
13.4 Market opportunities
- Presence of novel drug formulations in late stages of development
- Expanding research for development of novel therapies
- Increasing OTC abuse of drugs

14 Competitive Landscape

14.1 Overview
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
- Overview on factors of disruption
14.4 Industry risks
- Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled
- Companies covered
15.2 Company ranking index
- Company ranking index
15.3 Market positioning of companies
- Matrix on companies position and classification
15.4 A. Menarini Industrie Farma
- A. Menarini Industrie Farma - Overview
- A. Menarini Industrie Farma - Product / Service
- A. Menarini Industrie Farma - Key offerings
- SWOT
15.5 Aseric Pharma
- Aseric Pharma - Overview
- Aseric Pharma - Product / Service
- Aseric Pharma - Key offerings
- SWOT
15.6 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product / Service
- Aurobindo Pharma Ltd. - Key offerings
- SWOT
15.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
15.8 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
15.9 Dong A Socio Holdings Co. Ltd.
- Dong A Socio Holdings Co. Ltd. - Overview
- Dong A Socio Holdings Co. Ltd. - Product / Service
- Dong A Socio Holdings Co. Ltd. - Key offerings
- SWOT
15.10 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
15.11 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
15.12 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
15.13 Nippon Shinyaku Co. Ltd.
- Nippon Shinyaku Co. Ltd. - Overview
- Nippon Shinyaku Co. Ltd. - Business segments
- Nippon Shinyaku Co. Ltd. - Key offerings
- Nippon Shinyaku Co. Ltd. - Segment focus
- SWOT
15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
15.15 Sandoz Group AG
- Sandoz Group AG - Overview
- Sandoz Group AG - Product / Service
- Sandoz Group AG - Key offerings
- SWOT
15.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
15.17 SK Chemicals Co. Ltd.
- SK Chemicals Co. Ltd. - Overview
- SK Chemicals Co. Ltd. - Product / Service
- SK Chemicals Co. Ltd. - Key news
- SK Chemicals Co. Ltd. - Key offerings
- SWOT
15.18 Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries - Overview
- Sun Pharmaceutical Industries - Product / Service
- Sun Pharmaceutical Industries - Key news
- Sun Pharmaceutical Industries - Key offerings
- SWOT

16 Appendix

16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
16.3 Currency conversion rates for US$
- Currency conversion rates for US$
16.4 Research methodology
- Research methodology
16.5 Data procurement
- Information sources
16.6 Data validation
- Data validation
16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
16.8 Data synthesis
- Data synthesis
16.9 360 degree market analysis
- 360 degree market analysis
16.10 List of abbreviations
- List of abbreviations